Cancer associated fibroblast subtypes modulate the tumor-immune microenvironment and are associated with skin cancer malignancy
Agnes Forsthuber,Bertram Aschenbrenner,Ana Korosec,Tina Jacob,Karl Annusver,Natalia Krajic,Daria Kholodniuk,Sophie Frech,Shaohua Zhu,Kim Purkhauser,Katharina Lipp,Franziska Werner,Vy Nguyen,Johannes Griss,Wolfgang Bauer,Ana Soler Cardona,Benedikt Weber,Wolfgang Weninger,Bernhard Gesslbauer,Clement Staud,Jakob Nedomansky,Christine Radtke,Stephan N. Wagner,Peter Petzelbauer,Maria Kasper,Beate M. Lichtenberger
DOI: https://doi.org/10.1101/2023.05.03.539213
2024-09-05
Abstract:Cancer-associated fibroblasts (CAFs) play a key role in cancer progression and treatment outcome. This study dissects the yet unresolved intra-tumoral variety of CAFs in three skin cancer types (Basal Cell Carcinoma, Squamous Cell Carcinoma, and Melanoma) at molecular and spatial single-cell resolution. By integral analysis of the fibroblasts with the tumor microenvironment, including epithelial, mesenchymal, and immune cells, we characterize three distinct CAF subtypes: myofibroblast-like RGS5+ CAFs, matrix CAFs (mCAFs), and immunomodulatory CAFs (iCAFs). Notably, large cohort tissue analysis reveals marked shifts in CAF subtype patterns with increasing malignancy. Two CAF types exhibit immunomodulatory capabilities via distinct mechanisms. mCAFs synthesize extracellular matrix and have the ability to ensheath tumor nests, potentially limiting T cell invasion in low-grade tumors. In contrast, iCAFs are enriched in late-stage tumors, especially infiltrative BCC and high-grade melanoma, and express unexpectedly high mRNA and protein levels of cytokines and chemokines, pointing to their integral role in immune cell recruitment and activation. This finding is further supported by our observation that in vitro exposure of primary healthy fibroblasts to skin cancer cell secretomes induces an iCAF-like phenotype with immunomodulatory functions. Thus, targeting CAF variants, particularly the immunomodulatory iCAF subtype, holds promise for improved efficacy of immunotherapy in skin cancers.
Cancer Biology